Detailed price information for Travere Therapeutics Inc (TVTX-Q) from The Globe and Mail including charting and trades.
Travere Therapeutics is rated Buy, with a DCF-based fair value of ~$81 per share, implying 27% upside. Click here to read ...
Investor's Business Daily on MSN
IBD stock of the day, Travere Therapeutics, tests another breakout. Can the stock get any 'sweeter?'
Travere Therapeutics is Friday's IBD Stock Of The Day. As the Filspari story gets "sweeter," shares are clearing a fresh buy ...
Travere Therapeutics (NASDAQ:TVTX) is pursuing growth through expanded use of FILSPARI in rare kidney diseases while ...
Investor's Business Daily on MSN
Three biotech stocks stick out with their stellar charts
These biotech stocks all popped after their recent earnings reports. All three have outperformed 97% of stocks in the last 12 ...
Morningstar Quantitative Ratings for Stocks are generated using an algorithm that compares companies that are not under analyst coverage to peer companies that do receive analyst-driven ratings.
Travere Therapeutics Inc. Annual cash flow by MarketWatch. View TVTX net cash flow, operating cash flow, operating expenses and cash dividends.
Everest Medicines (HKEX 1952.HK, Everest, or the Company), a biopharmaceutical company focused on the discovery, clinical ...
Everest Medicines Limited a communiqué ses résultats financiers pour le semestre clos le 30 juin 2026. Sur cette période, la société a enregistré un chiffre d'affaires de 1 147,84 millions ...
Dette er Nesbø-stilen slik vi kjenner den best: Tett, effektiv og velkomponert. Nesbø vant i år sin tredje Rivertonpris for ...
Ligand Pharmaceuticals Inc () has held its Q2 earnings call. Read on for the main highlights of the call. Summer Sale - Claim 70% Off TipRanks. Unlock powerful investing tools wit ...
8月19日，港股创新药企业云顶新耀(01952.HK)披露2026年中期业绩。报告期内，公司实现总收入人民币11.48亿元，同比增长157%；剔除非现金项目后毛利率达到73.7%，非国际财务报告准则下实现净利润人民币9723万元，标志着 ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results